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A cute kidney injury (AKI) induced by contrast following percutaneous coronary intervention 
(PCI) is associated with increased short- and long-term 
mortality in patients with coronary artery disease [1].  
To prevent contrast-induced AKI,  infusion of saline has 
been used in clinical practice since 1980 [2].  Infusion of 
sodium bicarbonate was expected to be a replacement 
therapy to prevent contrast-induced AKI.  However,  
multicenter,  randomized trials have shown no advan-
tage of this method compared with infusion of saline 
[3 , 4].  A variety of pharmacotherapies have been evalu-
ated for prevention of contrast-induced AKI.  Infusion 
or oral administration of nicorandil,  which has dual 
properties of a nitrate and an ATP-sensitive K+ channel 
agonist with vasodilatory effects,  decreases the inci-
dence of contrast-induced AKI [5 , 6].  However,  the 
benefit of these therapies remains unclear.
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Remote ischemic preconditioning (RIPC) is a promising strategy for protecting against ischemic reperfusion 
injury.  This study is a secondary analysis of a randomized study that aimed to evaluate the effect of RIPC on the 
early increase in serum creatinine (SCr) following percutaneous coronary intervention (PCI),  which is associ-
ated with contrast-induced acute kidney injury.  Patients with stable angina undergoing elective PCI were 
assigned to control,  RIPC,  and continuous infusion of nicorandil (nicorandil) groups.  The endpoint of this 
study was the incidence of the early increase in SCr,  a predictor of contrast-induced acute kidney injury,  which 
was defined as either a > 20% or absolute increase by 0.3 mg/dl of SCr levels after 24 h of PCI.  This study 
included 220 patients for whom a dataset of SCr values was available.  The incidence of the early increase in SCr 
was significantly lower in the RIPC than in the control (1.3% vs 10.8%,  p= 0.03) group,  but was not significantly 
different between the nicorandil and control groups.  In multivariate analysis,  RIPC remained a significant fac-
tor associated with a reduction in the incidence of early increase in SCr.  RIPC reduces the incidence of early 
increase in SCr in patients with stable angina following elective PCI.
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Contrast-induced AKI is usually defined as an 
increase in in the serum creatinine (SCr) level from 
baseline 48 to 72 h after contrast exposure [7-10].  
However,  with the development of new technology,  
most patients are discharged in 1 or 2 days after PCI,  
without the measurement of SCr at 48-72 h after PCI.  
To stratify patients’ risks of contrast-induced AKI prior 
to PCI,  a scoring system is useful.  Inohara et al.  
reported that the AKI prediction model derived from 
the National Cardiovascular Data Registry (NCDR) was 
well-fitted to analysis of a Japanese PCI cohort [11].  
Meanwhile,  Ribichini et al.  evaluated predictors of con-
trast-induced AKI after angiography and PCI,  and 
found that an increase in SCr of 5% to 10% above base-
line at 12 h predicted the development of contrast- 
induced AKI [12].  Liu et al.  reported that long-term 
mortality in patients after coronary angiography was 
similar for patients with early (within 24 h) and late 
(24-48 h) increases in SCr ≥ 0.3 mg/dL or ≥ 50% [13].  
Thus,  the early increase in SCr after contrast exposure 
may be a useful predictor for contrast-induced AKI and 
its associated long-term mortality.
Remote ischemic preconditioning (RIPC) is defined 
as transient brief episodes of ischemia at a remote site 
before a subsequent prolonged ischemia/reperfusion 
injury of the target organ.  RIPC is an adaptational 
response that protects against an ischemic and reperfu-
sion insult [14].  Several studies have shown the tissue- 
protective effects of RIPC in various target organs,  
including the kidneys [8 , 15-20].  Therefore,  RIPC may 
offer a novel noninvasive treatment strategy for 
decreasing the incidence of AKI.
We recently reported a multicenter,  randomized 
trial that examined whether pre-procedural RIPC or 
intravenous nicorandil reduces periprocedural myocar-
dial injury in patients who undergo elective PCI for 
stable coronary artery disease.  This study showed that 
RIPC or intravenous nicorandil moderately reduced 
biomarker release and periprocedural myocardial 
injury,  but these results were not significant [21].  
Therefore,  an exploratory analysis to identify a popula-
tion in whom RIPC or intravenous nicorandil is effec-
tive was planned.  Considering the tissue-protective 
effects of RIPC in various organs,  RIPC could have a 
protective effect on contrast-induced AKI.  In our pre-
vious randomized study [21],  we collected serum creat-
inine value at baseline and 24 h after PCI.  We hypothe-
sized that RIPC reduced the incidence of the early 
increase in creatinine,  which is associated with the 
development of contrast-induced AKI.  Thus,  this study 
aimed to evaluate the effect of RIPC or nicorandil on the 
early increase in SCr as a substudy of our previous mul-
ticenter,  randomized study.
Materials and Methods
The main study (Cardiac Preconditioning Effect of 
Remote Ischemia and Nicorandil in Patients Undergoing 
Elective Percutaneous Coronary Intervention: RINC) 
was a prospective,  open-label,  multicenter,  random-
ized,  controlled trial,  which was conducted between 
February 2011 and January 2013 [21].  The current 
study was a post-hoc analysis of the RINC study.  The 
study was approved by the ethics committees of all par-
ticipating hospitals.  All participants provided written 
informed consent before enrolling.  This study was con-
ducted in accordance with the principles expressed in 
the Declaration of Helsinki.  The study is registered at 
the UMIN Clinical Trials Registry (UMIN000005607).
Patient population. Figure 1 shows a flow dia-
gram of the study.  Eligible patients were adults (> 20 
years old) who were diagnosed with silent myocardial 
ischemia or stable angina and planned to have elective 
PCI.  Patients were excluded for the following reasons:  
they had acute coronary syndrome,  they had contrain-
dications for intravenous nicorandil administration,  
they planned elective PCI for a chronic total occlusion 
lesion or PCI with a rotablator,  they were using sulfo-
nylurea drugs,  they had an aorta-venous shunt in one 
or both arms,  and their prognosis was regarded as < 12 
months [21 , 22].  In the main study,  396 patients 
underwent randomization.  In this post-hoc analysis,  
patients were included if blood samples for measuring 
SCr levels before PCI and 24 h after PCI were available.  
Finally,  220 patients were included in this post-hoc 
analysis (n = 74 in the control group,  n = 77 in the RIPC 
group,  and n = 69 in the nicorandil group).
Study protocol. The intervention protocol and 
PCI procedure have been described previously [21].  
Patients were randomly assigned to control,  RIPC,  or 
6 mg/h intravenous nicorandil (nicorandil) groups.  In 
patients who were assigned to the RIPC group,  5-min 
inflation of a blood pressure cuff to 200 mmHg around 
the upper arm,  followed by 5-min deflation of a cuff to 
0 mmHg was performed three times for at least 1 h each 
time before PCI.  This procedure was automatically per-
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formed by a newly developed automated continuous 
blood pressure device (FB-270; Fukuda Denshi,  
Tokyo).  In patients who were assigned to the nicorandil 
group,  4 mg of nicorandil was intravenously adminis-
tered for 5 min at least 1 h before PCI,  followed by 
continuous infusion of nicorandil (6 mg/h) for at least 
8 h during PCI.  The infusion was stopped at the direc-
tion of the attending doctor.  Patients in the control 
group did not receive any additional pre-treatment 
before PCI.  Blood samples were collected before PCI 
(until 2 days before the planned PCI) and at 24 h after 
PCI.  The total volume of drip infusion associated with 
PCI (> 1,500 ml or < 1,500 ml) was collected.
End points. The primary end point of this sub-
analysis was the incidence of the early increase in SCr 
following PCI.
Early increase in SCr was defined as either a > 20% 
increase or an absolute increase by 0.3 mg/dl of SCr 
24 h after PCI.  The definition of early increase in SCr 
was based on a previous study of the definition of AKI 
following angiography with use of contrast [23 , 10].
The incidence of early increase in SCr was also eval-
uated according to the Mehran Score and the tertile of 
contrast medium (first: 9-80 ml; second: 83-118 ml;  
third: 120-232 ml).  The Mehran score is used to pre-
dict the risk of developing contrast-induced AKI [24],  
and accounts for such factors as hypotension,  use of an 
intra-aortic balloon pump,  congestive heart failure,  
age,  anemia,  diabetes mellitus,  contrast media volume,  
and estimated glomerular filtration rate (eGFR).  
Mehran scores of < 5 , 6-10 , 11-15,  and > 15 were cate-
gorized as low,  moderate,  high,  and very high risk.
Statistical analysis. Continuous variables are 
presented as the mean ± standard deviation or as the 
median (25-75 th percentile),  as appropriate.  Categorical 
variables are presented as numbers and ratios (%).  
Continuous variables were compared using analysis of 
variance or the Kruskal-Wallis test,  as appropriate.  
Categorical variables were compared using Pearson’s 
chi-square test.  For multiple comparison,  the 
Bonferroni post-hoc test was applied.
We assumed that occurrence of renal failure event 
would be 20% in the control group,  and 4% in the RIPC 
group or nicorandil group as in previous studies 
[5 , 6 , 8 , 18 , 25 , 26].  To ensure that the two-sided signif-
icance level was 5% and the power was 90%,  77 
patients in each group were required.
Odds ratios (ORs) between groups and their 95% 
exact confidence intervals (CIs) were calculated.  In 
addition,  a multivariate logistic regression model was 
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Fig. 1　 Flow diagram of the study.  A total of 405 patients were enrolled in this study.  Among them,  396 patients underwent randomiza-
tion,  and 220 were included in the per-protocol set as the complete study population.
RIPC,  remote ichemic preconditioning; PCI,  percutaneous coronary intervention.
used to calculate the OR between study groups with 
adjustment for factors having p values < 0.10 in univar-
iate analysis (i.e.,  smoking),  as well as duration of blood 
sampling and total fluid volume.  All analyses were per-
formed with IBM SPSS version 25.  A p value < 0.05 was 
considered statistically significant.
Results
Study population. Table 1 shows the baseline 
patient characteristics in the control,  RIPC,  and 
nicorandil groups.  Among all patients,  the mean age,  
eGFR at baseline,  and volume of contrast medium used 
for PCI were 70.7±8.8 years,  64.3±16.5 ml/min/1.73 m2,  
and 103.2 ± 39.5 ml,  respectively.  These parameters 
were not significantly different among the three groups.  
Other baseline patient characteristics and medications 
were also not significantly different among the groups.
Primary end point. Of the 220 patients,  the early 
increase in SCr occurred in 11 patients.  First,  the inci-
dence of early increase in SCr was evaluated according 
to the Mehran score.  The incidence of the early increase 
in SCr in the low risk (n = 92),  moderate risk (n = 74),  
and high and very high risk (n = 54) groups was 1.1%,  
8.1%,  and 7.4%,  respectively (p= 0.08).  In addition,  the 
incidence of early increase in SCr was evaluated accord-
ing to the tertile of contrast medium.  The incidence of 
AKI in the first (n = 78),  second (n = 73),  and third 
(n = 68) tertiles was 3.9%,  4.1%,  and 0%,  respectively.
The incidence of the early increase in SCr (primary 
endpoint) was significantly lower in the RIPC group 
than in the control group (1 [1.3%] vs 8 [10.8%] 
patients,  p = 0.03),  but it was not significantly different 
between the nicorandil (2 [2.8%] patients) and control 
groups (p = 0.18) (Fig. 2).  A further analysis in patients 
with eGFR < 60 mL/min per 1.73 m2 was performed 
(control : n = 34; nicorandil : n = 28; RIPC: n = 34).  
The incidence of early increase in SCr was 9% (n = 3) in 
the control,  2% (n = 2) in the nicorandil,  and 0% in the 
RIPC group,  respectively,  and there was no significant 
difference between the control and nicorandil (p = 0.81) 
or between the control and the RIPC (p = 0.08) groups.
Independent association between the early increase 
in SCr and RIPC. To examine the association between 
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Age,  years 72±9 70±10 70±8 0.15
Male sex 51 (71) 53 (84) 59 (76) 0.46
Body mass index,  kg/m2 23.8±3.2 24.1±3.6 25.0±3.4 0.10
Diabetes mellitus 37 (50) 32 (46) 38 (49) 0.90
Hypertension 65 (88) 59 (86) 64 (83) 0.71
Smoking 45 (61) 49 (51) 52 (66) 0.42
Previous ASCVD 34 (49) 35 (51) 35 (45) 0.78
LDL-cholesterol,  mg/dl 90±29 91±31 89±24 0.92
Serum creatinine,  mg/dl 0.87±0.22 0.90±0.21 0.93±0.37 0.35
eGFR,  ml/min/1.73 m2 64±17 63±15 64±19 0.84
Hemoglobin A1c,  % 6.1±1.1 6.1±1.2 6.1±1.1 0.94
Contrast medium,  ml 100 [80-130] 105 [80-121] 102 [70-130] 0.89
Total volume of drip infusion (>1,500 ml) 34 (50) 41 (53) 28 (41) 0.29
Duration from baseline blood sampling to PCI (days) 5 [4-7] 6 [4-8] 6 [4-7] 0.80
Left ventricular ejection fraction,  % 61±11 61±11 64±9 0.20
Mehran score 7 [4-11] 6 [3-10] 6 [3-10] 0.98
Medications
　ACEI/ARB 52 (70) 42 (55) 45 (65) 0.12
　Statin 58 (78) 62 (81) 55 (80) 0.95
　Insulin 10 (14) 6 (7.8) 12 (17) 0.21
　Oral hypoglycemic agent 26 (35) 31 (40) 19 (28) 0.27
Data are presented as mean±standard deviation,  n (%),  or median [25-75 th percentile].
ACEI,  angiotensin-converting enzyme inhibitor; ARB,  angiotensin II receptor blocker; ASCVD,  atherosclerotic cardiovascular disease;  
eGFR,  estimated glomerular filtration rate; LDL,  low-density lipoprotein; RIPC,  remote ischemic preconditioning.
the early increase in SCr and RIPC,  151 patients in the 
control (n = 74) and the RIPC (n = 77) groups were ana-
lyzed.  Table 2 compares the patient characteristics 
between patients with and without the early increase in 
SCr.  There were no significant differences in character-
istics between the 2 groups.  Finally,  logistic regression 
analysis was performed (Table 3).  Multivariate analysis 
using factors that showed p values < 0.10 in univariate 
analysis,  the total volume of drip infusion,  and the 
duration from baseline blood sampling to PCI showed 
that RIPC remained a significant factor associated with 
a reduction in the early increase in SCr (odds ratio,  
0.12; 95% confidence interval,  0.01-0.96; p = 0.04).
Discussion
In this post-hoc analysis of a multicenter,  random-
ized,  controlled trial,  we showed that the incidence of 
the early increase in SCr in the RIPC group was signifi-
cantly lower than that in the control group.  However,  
the nicorandil group did not show a significantly lower 
incidence of the early increase in SCr compared with the 
control group.  This is the first multicenter trial to show 
the potential benefit of RIPC for preventing contrast- 
induced AKI following elective PCI in patients with 
stable coronary artery disease.
Several clinical studies have reported the effect of 
RIPC on renal outcomes [8 , 18-20].  A randomized trial 
by Zarbock et al.  reported that performing RIPC before 
open thoracic cardiac surgery prevented patients from 
having renal failure 72 h after surgery [20].  Similar 
studies have reported the protective effect of RIPC in the 
perioperative period,  which suggests that there is a 
renal protective effect of RIPC in highly invasive sur-
















Fig. 2　 Incidence of the early increase in serum creatinine post-
PCI.  The incidence of the early increase in serum creatinine follow-
ing PCI in the control,  RIPC,  and nicorandil groups is shown.  
Fisherʼs exact test was applied to compare the incidence of the 
early increase in serum creatinine following PCI between the RIPC 
and control groups or the nicorandil and control groups.
RIPC,  remote ischemic preconditioning.
Table 2　 Characteristics of patients with and without the early increase in serum creatinine in the control and RIPC groups
Early increase in serum creatinine
Presence (n=9) Absence (n=142) p value
Male 5 (55) 105 (74) 0.25
Age,  years 71±9 76±5 0.08
Diabetes mellitus 6 (66) 69 (49) 0.33
Hypertension 8 (88) 121 (85) 1.00
Dyslipidemia 7 (77) 116 (82) 0.67
eGFR <60 ml/min/1.73 m2 2 (22) 65 (46) 0.30
Previous ASCVD 5 (55) 64 (45) 0.73
Smoking 3 (33) 94 (66) 0.07
Contrast medium (ml) 100 [80-121] 100 [75-131] 0.82
ACEI/ARB 8 (89) 86 (61) 0.15
Statin 6 (66) 114 (80) 0.39
Oral hypoglycemic agent 3 (33) 54 (35) 1.00
RIPC 1 (11) 76 (54) 0.01
Total volume of drip infusion (>1,500 ml) 4 (44) 74 (52) 0.66
Duration from baseline blood sampling to PCI (days) 7 [4-9] 6 [4-8] 0.28
Data are presented as mean±standard deviation,  n (%),  or median [25-75th percentile].
RIPC,  remote ischemic preconditioning; eGFR,  estimated glomerular filtration rate; ASCVD,  atherosclerotic cardiovascular disease;  
ACEI,  angiotensin-converting enzyme inhibitor; ARB,  angiotensin II receptor blocker; PCI,  percutaneous coronary intervention.
gery.  However,  there are a limited number of studies in 
patients after angiography or PCI.  In a previous,  sin-
gle-center randomized trial,  the incidence of AKI in the 
control group was 40% [8],  higher than that in our 
RINC study (11%) in patients after elective angiogra-
phy.  Another multicenter randomized trial reported 
that the incidence of contrast-induced nephropathy in 
the RIPC group was not significantly lower than that in 
the control group (3.8% and 5.1%,  p = 0.74) [27].  There 
are some differences between these previous trials and 
our RINC study.  First,  patients in the previous trials 
had an eGFR < 60 ml/min/1.73 m2,  while patients in 
our RINC study had a mean eGFR of 64 ml/min/ 
1.73 m2.  Therefore,  the RINC study included patients 
with mild renal insufficiency.  Second,  in the previous 
trial,  measurement of SCr levels was performed until 
48 h after the procedure to define contrast-induced 
AKI.  However,  in our study,  SCr levels were checked 
once in 24 h after PCI.  The incidence of the early 
increase in SCr is associated with contrast-induced AKI,  
but is not generally used to define contrast-induced 
AKI.  Thus,  this study did not evaluate the incidence of 
contrast-induced AKI directly.  Third,  the use of con-
trast,  the PCI procedures and the prior infusion of 
saline or other fluids were controlled according to the 
patient’s baseline kidney function by physicians within 
the protocol of the main study to prevent large myocar-
dial injury,  which may be associated with AKI.  
However,  there are also several strengths of our study.  
First,  this study is the first multicenter trial to show the 
potential benefit of RIPC on contrast-induced renal 
injury in patients after PCI.  Second,  the occurrence of 
early increase in SCr has clinical relevance and impor-
tance for the development of contrast-induced AKI 
[12 , 13].  Therefore,  any reduction in the incidence of 
the early increase in SCr would provide practical benefit 
for patients following PCI.
The actual mechanism of RIPC remains controver-
sial,  but neuronal and hormonal pathways have been 
proposed to account for the protection against ischemic 
reperfusion injury.  [14 , 28].  We previously reported 
that three cycles of ischemia-reperfusion in an upper 
limb enhanced parasympathetic nerve activity in 
healthy subjects,  which might induce vasodilation [29].  
RIPC induces nitric oxide synthase,  which produces 
nitric oxide,  which is a humoral factor that exhibits 
vasodilatory activity in the manner of adenosine and 
bradykinin [30].  A clinical randomized trial showed 
that the significantly higher circulating nitric oxide level 
in an RIPC group compared to the control group was 
maintained until 24 h after cardiac surgery [31].  
Another study showed that RIPC induced a significant 
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Table 3　 Odds ratios for the early increase in serum creatinine
Univariate analysis Multivariate analysis
Odds ratio 95% CI p value Odds ratio 95% CI p value
RIPC 0.11 0.01-0.89 0.04 0.12 0.01-0.96 0.04
Male sex 0.44 0.11-1.73 0.23
Age 1.08 0.98-1.19 0.11
Diabetes mellitus 2.11 0.51-8.79 0.30
Dyslipidemia 0.78 0.15-3.99 0.78
Hypertension 1.39 0.17-11.68 0.76
eGFR <60 ml/min/1.73 m2 0.34 0.07-1.69 0.19
Previous ASCVD 1.52 0.39-5.91 0.54
Smoking 0.26 0.06-1.07 0.06 0.24 0.05-1.09 0.07
Contrast medium 0.98 0.96-1.01 0.19
ACEI/ARB 5.21 0.63-42.79 0.13
Statin 0.49 0.12-2.09 0.34
Oral hypoglycemic agent 0.82 0.19-3.39 0.78
Total volume of drip infusion (>1,500 ml) 0.66 0.16-2.76 0.57 0.75 0.18-3.10 0.69
Duration from baseline blood sampling to PCI (days) 1.06 0.87-1.30 0.57 1.09 0.88-1.34 0.44
Multivariate analysis included factors with p<0.1 in univariate analysis.
CI,  confidence interval; RIPC,  remote ischemic preconditioning; eGFR,  estimated glomerular filtration rate; ASCVD,  atherosclerotic car-
diovascular disease; ACEI,  angiotensin-converting enzyme inhibitor; ARB,  angiotensin II receptor blocker; PCI,  percutaneous coronary 
intervention.
decrease in the renal resistivity index through increased 
intra-renal perfusion in healthy volunteers [32].  In the 
target organ,  RIPC activates the phosphoinositide 3 
kinase/Akt/cyclic guanosine monophosphate/protein 
kinase G pathway,  which modulates mitochondrial 
ATP-sensitive K+ channels [28].  This pathway may pre-
vent cell damage.  With regard to the mechanism of 
RIPC in renal protection,  the following possibility 
should be considered.  Nephrons with a microvascular 
network are vulnerable to injury.  When contrast 
medium is used,  there is sustained (hours to days) 
intrarenal vasoconstriction and ischemic injury [33].  
This ischemic disorder triggers a cascade of oxidative 
injury causing death of renal tubular cells.  RIPC might 
provide the kidney with resistance to ischemic injury by 
reducing vessel resistance and increasing renal perfu-
sion.  Because the main study of this subanalysis was not 
designed to investigate the mechanisms of RIPC,  
change in neuronal and hormonal factors was not 
examined.  Further studies will be needed to elucidate 
the underlying mechanisms of RIPC.
Our study showed that nicorandil moderately 
reduced the incidence of the early increase in SCr,  but 
this effect was not statistically significant.  This finding 
is in line with previous studies showing the efficacy of 
nicorandil for avoiding AKI [6].  In that protocol,  
nicorandil was administered by injection of 4 mg fol-
lowed by infusion at 6 mg/h for 24 h and by oral 
administration,  based on our previous study showing 
that intravenous nicorandil in conjunction with coro-
nary angioplasty is associated with better functional and 
clinical outcomes in patients with an anterior acute 
myocardial infarction [34].  Therefore,  in this study,  
4 mg of nicorandil was intravenously administered for 
5 min at least 1 h before PCI,  followed by continuous 
infusion of nicorandil (6 mg/h) for at least 8 h [21].  
Nawa et al.  reported that creatinine values at 24 h after 
PCI in the continuous nicorandil infusion group were 
significantly lower than those in the control group [5].  
However,  our study failed to show significant reduction 
of the incidence of the early increase in SCr,  despite a 
longer duration of nicorandil administration than that 
in our study.  To achieve the maximum effect of 
nicorandil for preventing AKI,  the optimal dose and 
administration duration need to be clarified.
In this study,  we evaluated the effects of RIPC and 
nicorandil on renal function.  RIPC is probably medi-
ated by neural and hormonal factors [14 , 28] and can be 
applied to all patients with renal dysfunction undergo-
ing PCI.  Meanwhile,  nicorandil is a synthetic K-ATP 
channel activator and increases vascular nitric oxide 
content by activating endothelial nitric oxide synthase 
[35].  Nicorandil is also used widely in patients with 
renal dysfunction.  The combination of RIPC and 
nicorandil might have additive effects on renal function,  
although further studies will be needed to confirm this.
Limitations. This study had several limitations.  
First,  this study was a post-hoc analysis of a random-
ized,  controlled trial.  A small number of early increases 
in SCr occurred after PCI in the RIPC group and the 
nicorandil group.  Second,  the infusion volume,  such as 
for saline around PCI,  was not available in this sub-
analysis.  We cannot deny the possibility that some 
patients received additional infusion or other protective 
pretreatments for kidney function because the renal 
function of patients before PCI was not blind.  Third,  
almost half of the patients were excluded due to the lack 
of SCr after PCI,  although the number of patients satis-
fied our sample-size calculation.  When we examined 
the homogeneity of patient characteristics between this 
study and the main study in each group,  no significant 
differences were found (data not shown).  Fourth,  the 
early increase in SCr used in our study was different 
from the definition commonly used for contrast-induced 
AKI [24].  Contrast-induced AKI is usually defined as 
an increase in the SCr level from baseline at 48 to 72 h 
after contrast exposure [7-10].  In this study,  blood 
sampling was performed only once,  at 24 h after PCI.  
However,  early increases in SCr have been associated 
with the development of contrast-induced AKI and 
prognosis [12 , 13],  and are thus of clinical importance.  
Fifth,  a sham RIPC group was not set in this study.  
Therefore,  we cannot completely rule out that this non-
blinded intervention affected the outcomes.
In conclusion this secondary analysis of the RINC 
study shows that RIPC significantly reduces the inci-
dence of the early increase in SCr following elective PCI 
in patients with stable angina.  Our study suggests that 
RIPC was beneficial for renal protection in these 
patients.  Further investigation using a multicenter,  
prospective study is required to evaluate the effect of 
RIPC on contrast-induced AKI following PCI in 
patients with stable angina.
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